British Land Company PLC (BLND)
London Exchange · UK · prices in GBX · close of 22 Oct 2026
Key indicators
| Last close | GBX 418.60 |
|---|---|
| 52-week range | 335.40 – 451.60 |
| Return, 1 month / 3 months | +4.1% / −4.4% |
| Return, 1 year / 3 years | +7.5% / +40.9% |
| Trend | Uptrend |
| RSI (14) | 60 |
| Volatility (1 year) | 24.8% |
| Worst drawdown (1 year) | -19.1% |
| Average daily value traded | 1,292.33M GBX |
| Dividend yield | 5.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
British Land Company is a property company based in the United Kingdom that owns, manages and develops commercial real estate. Its portfolio centres on offices in London, including large campus-style developments, together with retail and leisure properties such as shopping centres and retail parks around the country. The company leases space to businesses and retailers and works on development projects that add new buildings to its estate. Its customers are mainly corporate occupiers and retail tenants.
The shares are listed on the London Exchange in UK under the code BLND, and the price on this page is in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
British Land Company PLC (BLND) trades on the London Exchange in UK. It last closed at GBX 418.60 on 22 October 2026.
Its price-based Market X-Ray is 70 out of 100 (a strong price profile), ranking 525 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 7.5% and over the last three months it fell 4.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 64 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 3.7% | ||
| From 52-week high | -6.6% | ||
| Momentum | 50 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -4.4% | ||
| 6-month return | 5.4% | ||
| 12-month return, skipping the last month | 3.3% | ||
| Stability (higher is calmer) | 75 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 24.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -19.1% | ||
| Liquidity | 97 · Strong | Trades actively. | |
| Average daily value traded | 1,292.33M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 82 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 5.5% | ||
| Years with dividends | 6 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
- Income: Dividend is high and has been paid regularly.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −0.9% |
|---|---|
| 1 month | +4.1% |
| 3 months | −4.4% |
| 6 months | +5.4% |
| 1 year | +7.5% |
| 3 years | +40.9% |
| 5 years | −13.9% |
Signals
| 50-day / 200-day average | 409.32 / 403.76 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 9.31 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 Jun 2026 | GBP 0.1080 |
| 4 Dec 2025 | GBP 0.1232 |
| 19 Jun 2025 | GBP 0.1056 |
| 5 Dec 2024 | GBP 0.1224 |
| 20 Jun 2024 | GBP 0.1064 |
| 23 Nov 2023 | GBP 0.1216 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.